Skye Bioscience (SKYE) Competitors

Prime Medicine (NYSE:PRME) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Do analysts prefer PRME or SKYE?

Prime Medicine currently has a consensus price target of $9.25, indicating a potential upside of 137.18%. Skye Bioscience has a consensus price target of $16.60, indicating a potential upside of 346.24%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Skye Bioscience	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is PRME or SKYE more profitable?

Skye Bioscience's return on equity of -53.92% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-107.87%	-74.97%
Skye Bioscience	N/A	-53.92%	-48.58%

Does the media prefer PRME or SKYE?

In the previous week, Prime Medicine had 6 more articles in the media than Skye Bioscience. MarketBeat recorded 8 mentions for Prime Medicine and 2 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.63 beat Prime Medicine's score of 0.48 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, PRME or SKYE?

Skye Bioscience has lower revenue, but higher earnings than Prime Medicine. Skye Bioscience is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$3.85M	136.38	-$198.13M	-$1.61	-2.42
Skye Bioscience	N/A	N/A	-$26.57M	-$0.82	-4.54

Do institutionals and insiders believe in PRME or SKYE?

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 22.9% of Prime Medicine shares are owned by insiders. Comparatively, 4.5% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, PRME or SKYE?

Prime Medicine has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.

Summary

Skye Bioscience beats Prime Medicine on 8 of the 15 factors compared between the two stocks.